Palvella Therapeutics Inc (PVLA) Stock Price, Quote & News

Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 253 1461

Website: palvellatx.com

Address:

353 W. Lancaster Avenue, Suite 200, Wayne, United States

Quantumup May. 12 at 11:55 AM

Stephens🏁 $PVLA OW; $220, and said, (Q)TORIN' Through Rare Skin Diseases; Initiating OW/Vol. $TARA $NVS PFE Here's what else Stephens said in its initiation report: https://x.com/Quantumup1/status/2054167804635382106?s=20

0 · Reply

MarketBeat May. 8 at 10:15 PM

Palvella Therapeutics Q1 Earnings Call Highlights $PVLA https://www.marketbeat.com/instant-alerts/palvella-therapeutics-q1-earnings-call-hi

0 · Reply

focafoca99 May. 7 at 1:33 PM

$PVLA released its Q1 2026 results for the quarter ended March 31, 2026.

0 · Reply

StocktwitsEarnings May. 7 at 12:37 PM

$PVLA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.20 down -62.16% YoY • Palvella Therapeutics believes its cash and short-term investments of $261.9M as of March 31, 2026, will fund operations for at least twelve months; however, additional capital may be needed thereafter.

0 · Reply

BillionerOfKing Apr. 28 at 8:53 PM

$PVLA Current Stock Price: $125.96 Contracts to trade: $125.0 PVLA May 15 2026 Call Entry: $8.00 Exit: $12.06 ROI: 51% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Merlintrader Apr. 26 at 5:56 PM

$PVLA Palvella Therapeutics (Nasdaq: $PVLA): Rare Skin Disease Catalyst Ahead of ISSVA 2026 https://www.merlintrader.com/palvella-therapeutics-april2026-deepdive/

0 · Reply

Doozio Apr. 19 at 3:26 PM

$PVLA powerful 🧠👀 to give YO a 🪧 NXT stop ☝️♾️ ONTO 🐒🍌🧠⏰♾️

0 · Reply

Quantumup Apr. 17 at 1:05 PM

BofA⬆️ $RLAY's PT and said: Previewing upcoming data in rare disease with unmet need; reit Buy, PO to $21—Higher PO on higher conviction for expanding opportunity $PVLA TARA $CELC RHHBY NVS LLY AZN BofA added—We preview initial clinical data for Relay's zovegalisib in vascular malformation (VM), ahead of late-breaking presentation at ISSVA (May 20). We believe the drug could differentiate from other treatments for this disease. This leads us to raise our PO to $21 (from $15) after adding risk-adjusted VM forecast ($1BN+ nominal) in our model. RLAY has had a strong run YTD (+83% vs +12% XBI) amid upcoming catalysts and peer group consolidation. Even with growing attention around the upcoming data, we think RLAY's ongoing development for breast cancer (2L) and cash position support today's valuation. We see further upside potential from: 1) data further supporting zovega as a leading treatment for VM, 2) the drug expanding into earlier-stage breast cancer. Reiterate Buy.

1 · Reply

focafoca99 Apr. 13 at 3:34 PM

$PVLA added rare-skin-disease specialist and investor John Doux to its board.

0 · Reply

focafoca99 Apr. 7 at 9:15 PM

$PVLA added Kent Taylor as senior vice president of sales to strengthen its commercial buildout.

0 · Reply